Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients

Published:2024-05-09 Issue:6 Volume:40 Page:967-975
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Jung Hye-In¹,Kwon Sun-Hong¹²,Nam Jin Hyun³,Cho Jeong-Yeon¹,Lee Eui-Kyung¹

Affiliation:

1. School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

2. Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK

3. Division of Big Data Science, Korea University Sejong Campus, Sejong, South Korea

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2349741

Reference35 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. National Cancer Institute Surveillance E Program ER. Cancer stat facts: female breast cancer subtypes. 2021. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html

3. Korean Breast Cancer Society. Breast Cancer Facts & Figures 2022. Seoul: Korean Breast Cancer Society; 2022.

4. CDK4/6 inhibition in breast cancer: current practice and future directions

5. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP